Winslow Asset Management Inc. lowered its holdings in Pfizer, Inc. (NYSE:PFE) by 6.3% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,111 shares of the biopharmaceutical company’s stock after selling 1,275 shares during the period. Winslow Asset Management Inc.’s holdings in Pfizer were worth $642,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Shine Investment Advisory Services Inc. bought a new stake in Pfizer in the 2nd quarter valued at about $102,000. D. Scott Neal Inc. boosted its holdings in Pfizer by 19.3% in the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 504 shares during the period. Franklin Parlapiano Turner & Welch LLC bought a new stake in Pfizer in the 1st quarter valued at about $121,000. Cascade Investment Advisors Inc. boosted its holdings in Pfizer by 89.1% in the 2nd quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 2,200 shares during the period. Finally, Perennial Advisors LLC boosted its holdings in Pfizer by 7.9% in the 2nd quarter. Perennial Advisors LLC now owns 5,132 shares of the biopharmaceutical company’s stock valued at $172,000 after purchasing an additional 376 shares during the period. 69.34% of the stock is owned by hedge funds and other institutional investors.

Several brokerages have recently commented on PFE. BMO Capital Markets upgraded shares of Pfizer from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $33.00 to $37.00 in a research report on Wednesday, August 2nd. UBS AG restated a “buy” rating and issued a $38.00 target price on shares of Pfizer in a research report on Monday, July 31st. ValuEngine upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Friday, October 6th. Zacks Investment Research cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, Morgan Stanley upgraded shares of Pfizer from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $35.00 to $39.00 in a research report on Wednesday, September 20th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have issued a buy rating to the stock. Pfizer has a consensus rating of “Buy” and an average target price of $38.66.

In related news, insider Alexander R. Mackenzie sold 14,700 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total transaction of $518,910.00. Following the completion of the transaction, the insider now directly owns 117,432 shares in the company, valued at approximately $4,145,349.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 7,350 shares of the company’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $34.00, for a total transaction of $249,900.00. Following the transaction, the insider now owns 132,124 shares of the company’s stock, valued at $4,492,216. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 366,557 shares of company stock valued at $12,532,406. 0.06% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/winslow-asset-management-inc-sells-1275-shares-of-pfizer-inc-pfe/1723781.html.

Pfizer, Inc. (PFE) opened at $35.43 on Friday. The stock has a market cap of $211,217.66, a P/E ratio of 14.17, a P/E/G ratio of 2.51 and a beta of 1.01. Pfizer, Inc. has a 12-month low of $30.51 and a 12-month high of $36.78. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The firm’s quarterly revenue was up .9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.61 EPS. analysts anticipate that Pfizer, Inc. will post 2.6 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Friday, November 10th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 3.61%. The ex-dividend date is Thursday, November 9th. Pfizer’s dividend payout ratio is 79.01%.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.